JPRN-UMIN000006646
Completed
N/A
Safety, efficacy and immunogenicity of concomitant interferon alpha and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma - Clinical study of combined interferon alpha and autologous tumor lysate-pulsed dendritic cell therapy for advanced renal cell carcinoma
ConditionsRenal cell carcinoma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Renal cell carcinoma
- Sponsor
- The University of Tokyo Hospital
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have: \-Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; \-Serious drug allergy; \-Active infections; \-Serious cardiac disease; \-Active autoimmune diseases; \-Continuous systemic administration of steroids within 4 weeks; \-Other cancers.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Safety, efficacy and immunogenicity of concomitant molecular target drug or cytokine therapy and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinomaJPRN-UMIN000014703The University of Tokyo Hospital15
Active, Not Recruiting
Phase 1
Concomitant administration of the Novavax vaccine and a 20-valent pneumococcal conjugate vaccine in adults aged =60 yearsVaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults (age >60 years). Given their wide application, co-administration of pneumococcal and Covid-19 vaccines may support broad population-wide coverage. However, it is unclear whether the co-administration of the new, Omicron-adapted Novavax (NVX XBB.1.5) vaccine and a 20-valent pneumococcal conjugate vaccine results in lower immunogenicity than the administration of either alone.Therapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2022-004118-12-ATMedical University of Vienna256
Recruiting
N/A
Safety and efficacy of combination immunotherapy with nivolumab and ipilimumab for elderly lung cancer patients: a cohort studyJPRN-UMIN000046353ational Hospital Organization Kyoto Medical Center60
Not Yet Recruiting
N/A
Evaluation of the Immunogenicity of Concomitant Administration of Novel Oral Polio Type 2 Vaccine (nOPV2) with Sabin OPV in Children aged 6 - 59 months in MozambiquePoliovirusPACTR202404654347323World Health Organization888
Not Yet Recruiting
Phase 1
Safety, preliminary efficacy and immunogenicity of traditional Chinese medicine miRNA hydrogel in the treatment of eczema: a randomized, double-blind, placebo-controlled, dose-increasing clinical studyeczemaITMCTR2000003604Shanghai Skin Disease Hospital